CY2016053I1 - Μεθοδοι αγωγης χρησιμοποιωντας φαρμακευτικες ουσιες συλληψης αμμωνιας - Google Patents

Μεθοδοι αγωγης χρησιμοποιωντας φαρμακευτικες ουσιες συλληψης αμμωνιας

Info

Publication number
CY2016053I1
CY2016053I1 CY2016053C CY2016053C CY2016053I1 CY 2016053 I1 CY2016053 I1 CY 2016053I1 CY 2016053 C CY2016053 C CY 2016053C CY 2016053 C CY2016053 C CY 2016053C CY 2016053 I1 CY2016053 I1 CY 2016053I1
Authority
CY
Cyprus
Prior art keywords
ammonia
treatment methods
pharmaceutical substances
tracking
tracking pharmaceutical
Prior art date
Application number
CY2016053C
Other languages
English (en)
Other versions
CY2016053I2 (el
Original Assignee
Horizon Therapeutics, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41255339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2016053(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Horizon Therapeutics, Llc filed Critical Horizon Therapeutics, Llc
Publication of CY2016053I2 publication Critical patent/CY2016053I2/el
Publication of CY2016053I1 publication Critical patent/CY2016053I1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806Determination of free amino acids
    • G01N33/6812Assays for specific amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/08Hepato-biliairy disorders other than hepatitis
    • G01N2800/085Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/34Genitourinary disorders
    • G01N2800/347Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
CY2016053C 2008-04-29 2016-12-22 Μεθοδοι αγωγης χρησιμοποιωντας φαρμακευτικες ουσιες συλληψης αμμωνιας CY2016053I1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4883008P 2008-04-29 2008-04-29
US9323408P 2008-08-29 2008-08-29
PCT/US2009/030362 WO2009134460A1 (en) 2008-04-29 2009-01-07 Methods of treatment using ammonia-scavenging drugs

Publications (2)

Publication Number Publication Date
CY2016053I2 CY2016053I2 (el) 2017-06-28
CY2016053I1 true CY2016053I1 (el) 2017-06-28

Family

ID=41255339

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20161100962T CY1118543T1 (el) 2008-04-29 2016-09-28 Μεθοδοι αγωγης χρησιμοποιωντας φαρμακευτικες ουσιες συλληψης αμμωνιας
CY2016053C CY2016053I1 (el) 2008-04-29 2016-12-22 Μεθοδοι αγωγης χρησιμοποιωντας φαρμακευτικες ουσιες συλληψης αμμωνιας
CY20181101231T CY1121288T1 (el) 2008-04-29 2018-11-21 Μεθοδος αγωγης χρησιμοποιωντας φαρμακευτικες ουσιες συλληψης αμμωνιας

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20161100962T CY1118543T1 (el) 2008-04-29 2016-09-28 Μεθοδοι αγωγης χρησιμοποιωντας φαρμακευτικες ουσιες συλληψης αμμωνιας

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20181101231T CY1121288T1 (el) 2008-04-29 2018-11-21 Μεθοδος αγωγης χρησιμοποιωντας φαρμακευτικες ουσιες συλληψης αμμωνιας

Country Status (12)

Country Link
US (2) US8642012B2 (el)
EP (2) EP2330892B1 (el)
CA (1) CA2735218A1 (el)
CY (3) CY1118543T1 (el)
DK (1) DK2330892T3 (el)
GB (1) GB2470310A (el)
HU (1) HUS1600057I1 (el)
LT (1) LTC2330892I2 (el)
NL (1) NL300854I2 (el)
NO (1) NO2016023I2 (el)
PL (1) PL3133396T3 (el)
WO (1) WO2009134460A1 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009134460A1 (en) 2008-04-29 2009-11-05 Hyperion Therapeutics Methods of treatment using ammonia-scavenging drugs
EP3100610A1 (en) 2009-07-24 2016-12-07 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
US8404215B1 (en) * 2011-09-30 2013-03-26 Hyperion Therapeutics, Inc. Methods of therapeutic monitoring of nitrogen scavenging
DK2846791T3 (en) 2012-04-20 2017-03-27 Horizon Therapeutics Llc HPN-100 FOR USE IN TREATMENT OF NITROGEN RETENTION DISORDER
EP3335735A1 (en) * 2012-11-21 2018-06-20 Horizon Therapeutics, LLC Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy
WO2015057747A1 (en) 2013-10-14 2015-04-23 Hyperion Therapeutics, Inc. Methods of treating urea cycle disorders
RU2016123169A (ru) 2013-11-14 2017-12-19 Ультраджиникс Фармасьютикал Инк. Твердые композиции триглицеридов и их применение
US10369124B2 (en) 2014-04-30 2019-08-06 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
EP3013372B1 (en) * 2014-06-04 2019-07-10 Immedica Pharma AB Methods for treating urea cycle disorders to prevent hyperammonemic crises by controlling blood ammonia levels
JP6342575B2 (ja) 2014-08-13 2018-06-13 ザ・ジョンズ・ホプキンス・ユニバーシティー 脳腫瘍への選択的デンドリマー送達
JP7088473B2 (ja) 2015-10-29 2022-06-21 ザ・ジョンズ・ホプキンス・ユニバーシティー ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
WO2018170234A1 (en) 2017-03-15 2018-09-20 President And Fellows Of Harvard College Methods and compositions for treating cancer
BR112019024750A2 (pt) * 2017-05-24 2020-06-09 Thoeris Gmbh uso de glutamina sintetase no tratamento da hiperamonemia
US11517547B2 (en) 2017-06-28 2022-12-06 Baylor College Of Medicine Combination therapy to treat urea cycle disorders
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
CA3163892A1 (en) 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to the eye

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) * 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
ATE201013T1 (de) 1995-02-07 2001-05-15 Brusilow Entpr Llc Triglyceride und ethylester von phenylalkansäuren und phenylalkensäuren zur behandlung verschiedener erkrankungen
DE19805854C1 (de) * 1998-02-13 1999-05-12 Claas Usines France Schalteinrichtung für Schneidmesser
US6219567B1 (en) * 1999-06-21 2001-04-17 Cardiox Corporation Monitoring of total ammoniacal concentration in blood
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
ATE457187T1 (de) * 2004-11-26 2010-02-15 Ucl Business Plc Zusammensetzungen mit ornithin und phenylacetat oder phenylbutyrat zur behandlung von hepatischer enzephalopathie
US20060135612A1 (en) * 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
JP5468015B2 (ja) 2008-01-08 2014-04-09 アクセリア ファーマシューティカルズ 抗菌ペプチド系に対する作動薬
WO2009134460A1 (en) 2008-04-29 2009-11-05 Hyperion Therapeutics Methods of treatment using ammonia-scavenging drugs
EP2338050A1 (en) 2008-08-29 2011-06-29 Ucyclyd Pharma, Inc. Dosing and monitoring patients on nitrogen-scavenging drugs

Also Published As

Publication number Publication date
US8642012B2 (en) 2014-02-04
GB201013468D0 (en) 2010-09-22
EP3133396B1 (en) 2018-09-05
NO2016023I1 (no) 2016-12-14
CY2016053I2 (el) 2017-06-28
EP2330892A1 (en) 2011-06-15
US20100008859A1 (en) 2010-01-14
NO2016023I2 (no) 2016-12-27
GB2470310A (en) 2010-11-17
US20140256807A1 (en) 2014-09-11
LTPA2016041I1 (lt) 2017-01-10
EP2330892A4 (en) 2012-01-11
PL3133396T3 (pl) 2019-03-29
DK2330892T3 (en) 2016-08-22
EP3133396A1 (en) 2017-02-22
NL300854I2 (el) 2017-02-02
CY1121288T1 (el) 2020-05-29
CY1118543T1 (el) 2017-06-28
HUS1600057I1 (hu) 2017-01-30
WO2009134460A1 (en) 2009-11-05
EP2330892B1 (en) 2016-06-29
LTC2330892I2 (lt) 2018-06-11
CA2735218A1 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
CY2016053I2 (el) Μεθοδοι αγωγης χρησιμοποιωντας φαρμακευτικες ουσιες συλληψης αμμωνιας
BRPI0914294A2 (pt) aparelho de tratamento de cápsulas
BRPI0910854A2 (pt) métodos de tratamento
BRPI0920521A2 (pt) combinação farmacêutica
BRPI0910259A2 (pt) métodos de tratamento de inflamação
IT1391555B1 (it) Apparato trattamento extracorporeo sangue
DK2274032T3 (da) Anordning til medicinindgivelse
BRPI0914841A2 (pt) aparelho de massagem
BRPI0920514A2 (pt) infusão de fármacos
DK2330887T3 (da) Behandlingsindretning
DK2285413T3 (da) Farmaceutisk sammensætning
BRPI0915822A2 (pt) dispositivo médico
BRPI0917684A2 (pt) método terapêutico homeopático
BRPI0921654A2 (pt) formulação farmacêutica
BRPI0914151A2 (pt) distribuidor de medicamento e método
BRPI0921313A2 (pt) composição farmaucêutica
DK2271618T3 (da) Farmaceutiske forbindelser
HRP20181877T1 (hr) Postupci za liječenje lijekovima koji uklanjaju amonijak
BRPI0912171A2 (pt) composição farmacêutica
IT1390848B1 (it) Composti farmaceutici
BRPI0921301A2 (pt) composição farmacêutica
DK2346559T3 (da) Medicinsk anordning
FR2937843B1 (fr) Paravent medical
FI20080332A0 (fi) Terapeuttisia molekyylejä
FI8168U1 (fi) Puunkäsittelylaite